Financials
Financial year 2025
DR.SASKIA ROBBRECHT, inwendige geneeskunde-endocrinologie from Zele, company number BE0899915916, closed financial year 2025 with a result of € 142,331 after tax. For that financial year DR.SASKIA ROBBRECHT, inwendige geneeskunde-endocrinologie recorded a gross margin of € 279,789 and equity of € 1.3 million. Compared with financial year 2024, the result moved from € 135,573 to € 142,331. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on February 5, 2026.
€ 1.3 million
▲ 12% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 142,331
▲ 5% vs 2024
Profit after tax over the fiscal year.
€ 241,481
▲ 35% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 1.2 million.
People and assets in 2025
€ 114
▼ 58% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 337,401
▼ 14% vs 2024
€ 37,428 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.
€ 17,588
▼ 4% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 8,200
▼ 37% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 260,345 | € 304,733 | € 292,798 | € 279,789 | ▼ 4% |
| Profit after taxes | € 120,175 | € 148,123 | € 135,573 | € 142,331 | ▲ 5% |
| Equity | € 901,496 | € 1,049,619 | € 1,185,191 | € 1,327,523 | ▲ 12% |
| Total debts | € 781,288 | € 692,009 | € 626,018 | € 564,793 | ▼ 10% |
| Cash | € 267,270 | € 265,010 | € 179,393 | € 241,481 | ▲ 35% |
| Land & buildings | € 1,156,282 | € 1,104,966 | € 1,049,452 | € 1,001,661 | ▼ 5% |
| Retained profit | € 791,496 | € 939,619 | € 1,075,191 | € 1,217,523 | ▲ 13% |
| Dividend | € 28,397 | € 0 | € 0 | € 0 | |
| Bank debt | € 533,817 | € 466,772 | € 391,505 | € 337,401 | ▼ 14% |
| Balance sheet total | € 1,682,784 | € 1,741,627 | € 1,811,209 | € 1,892,316 | ▲ 4% |
Key figures of DR.SASKIA ROBBRECHT, inwendige geneeskunde-endocrinologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to DR.SASKIA ROBBRECHT, inwendige geneeskunde-endocrinologie?
What happened at DR.SASKIA ROBBRECHT, inwendige geneeskunde-endocrinologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 142,331 (▲ 5% vs 2024). filed late Source: NBB ↗
- Saskia ROBBRECHT became a director. NBB
- New establishment in Zele. KBO
- Start of the company according to the CBE. KBO
In short
From € 120,175 profit in 2022 to € 142,331 profit in 2025.
Paid € 229,103 in corporate taxes since 2022.
Best year ever: 2023, with € 148,123 profit.
Paid out € 28,397 in dividends to the owners in total.
A new publication or filing at DR.SASKIA ROBBRECHT, inwendige geneeskunde-endocrinologie? We notify you, reason included.
Follow DR.SASKIA ROBBRECHT, inwendige geneeskunde-endocrinologieDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind DR.SASKIA ROBBRECHT, inwendige geneeskunde-endocrinologie is Saskia ROBBRECHT.
Directors
According to the 2025 annual accounts
Saskia ROBBRECHT
Bestuurder
since 2024
Establishments
Establishment units
Physical locations of this company
Scheldestraat 113
9240 Zele
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0899.915.916
- VAT number
- BE 0899.915.916
- Registered office
- Scheldestraat 113, 9240 Zele
- Names & denominations
- DR.SASKIA ROBBRECHT, inwendige geneeskunde-endocrinologie
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 18 August 2008
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Activiteiten van medisch specialisten
Overige persoonlijke diensten
Andere vormen van maatschappelijke dienstverlening zonder huisvesting, neg